Yubo International Biotech Limited's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Yubo International Biotech Limited's ROA in the second quarter of 2026?
Yubo International Biotech Limited recorded a cumulative net loss of $-1 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -130.04%.

However, within the Healthcare sector 782 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4315, from total ROA ranking in the first quarter of 2026 at 5011.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-36.07 %	-39.14 %	-44.81 %	-42.37 %	-39.17 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-1	-1	-1	-1	-2
Return On Assets (TTM)	-130.04 %	-114.06 %	-118.25 %	-111.63 %	-119.15 %
MAGAA's Total Ranking	# 4315	# 5011	# 4422	# 4514	# 4597
Total Assets (TTM) in million	1	1	1	1	1
Seq. Total Assets Change	-5.3 %	-16.2 %	-11.13 %	-9.36 %	-9.85 %
Seq. Net Income Change	-	-	-	-	-

MAGAA's 5 Years Annual ROA >> Back to MAGAA Management Effectiveness >> Compare MAGAA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 182
Sector	# 783
Overall	# 4313

Return On Assets Statistics
High	Average	Low
-27.58 %	-1323.74 %	-7507.69 %
(Sep 30 2023)		(Nov 30 2017)

Financial Statements
Yubo International Biotech Limited's Assets	$ 1 million	MAGAA's Balance sheet
Yubo International Biotech Limited's Income	$ 0 million	Quarterly MAGAA's Income Statement
MAGAA's Income by Division		See MAGAA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-44.81 %	-7.95 %	-29.01 %	-48.8 %	458623.4 %
Total Assets in million	1	2	2	2	5
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-1	-2	-1	-1	-2
Annual Return On Assets	-140.23 %	-102.22 %	-71.68 %	-51.31 %	-33.62 %

MAGAA's 5 Years Annual ROA >> Back to MAGAA Management Effectiveness >> Compare MAGAA ROA to its Competitors

More Return On Assets Ratios
MAGAA's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MAGAA's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MAGAA's Competitors
Subscribers only: Roa for Yubo International Biotech Limited's Suppliers
Subscribers only: Return On Assets for MAGAA's Customers

You may also want to know
MAGAA's Roi	MAGAA's Inventory Turnover Ratio	MAGAA's Growth Rates	MAGAA's Dividend Comparisons
	MAGAA's Profitability Ratios	MAGAA's Asset Turnover Ratio	MAGAA's Dividend Growth
MAGAA's Roe	MAGAA's Valuation Ratios	MAGAA's Financial Strength Ratios	MAGAA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-15T07:30:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.